Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?

Loukman Omarjee (1, 2) , Olivier Meilhac (3, 4) , Frédérique Perrot (5) , Anne Janin (6) , Guillaume Mahe (7, 1)

1 CIC - Centre d'Investigation Clinique [Rennes]
2 NuMeCan - Nutrition, Métabolismes et Cancer
3 DéTROI - Diabète athérothrombose et thérapies Réunion Océan Indien
4 CHU La Réunion - Centre Hospitalier Universitaire de La Réunion
5 Chercheur indépendant
6 MASCOT (UMR_S_942 / U942) - Marqueurs cardiovasculaires en situation de stress
7 CHU Pontchaillou [Rennes]

Keywords: COVID-19; Neutrophil extracellular traps; P2Y12 inhibitor; Ticagrelor; Platelets – Neutrophils aggregates; Sepsis-induced coagulopathy; Vascular leakage

Domains: Life Sciences [q-bio]; Life Sciences [q-bio]; Immunology

Loukman Omarjee, Olivier Meilhac, Frédérique Perrot, Anne Janin, Guillaume Mahe. Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?. Clinical Immunology, 2020, 216, pp.108468. ⟨10.1016/j.clim.2020.108468⟩. ⟨hal-02859926⟩